Alethia Biotherapeutics Inc., a Montréal, Québec, Canada-based biotechnology company focusing on the development of therapeutic monoclonal antibodies, has closed a new financing.
Update: The investment amounts to $4.7m.
The amount was not disclosed.
The company intends to use the proceeds to advance its lead bone antiresorprtive candidate AB-25E9 into the studies required to submit an IND.
Created in 2002 and led by Mr. Yves Cornellier, President & CEO, and Dr. Mario Filion, CSO, Alethia develops monoclonal antibody therapeutics to novel clinically relevant targets identified using its patented STAR discovery technology. It has developed a pipeline of novel, clinically relevant therapeutic targets that included Siglec-15, a regulator of osteoclast differentiation and function.